STAT3 and non-Hodgkin lymphoma: For example, Han et al. [68] demonstrated that overexpression of SHP1 in ALK+ ALCL cells—a distinct type of non-Hodgkin lymphoma—which are deficient in SHP1, reversed JAK3 and STAT3 activation, which corresponded with a decrease in STAT3 targets.